Published in Br J Cancer on February 14, 2012
Minor Cytological Abnormalities and up to 7-Year Risk for Subsequent High-Grade Lesions by HPV Type. PLoS One (2015) 0.80
Residual disease and HPV persistence after cryotherapy for cervical intraepithelial neoplasia grade 2/3 in HIV-positive women in Kenya. PLoS One (2014) 0.79
Diagnostic Approach to Patients with Atypical Squamous Cells of Undetermined Significance Cytologic Findings on Cervix. Med Arch (2016) 0.78
Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol (1999) 40.46
The causal relation between human papillomavirus and cervical cancer. J Clin Pathol (2002) 14.73
Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med (2007) 9.53
Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol (2008) 6.20
The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst (2005) 6.03
GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J Clin Microbiol (2002) 5.63
Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol (2011) 5.59
Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med (2007) 5.57
Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet (2003) 5.39
Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ (2008) 4.77
The carcinogenicity of human papillomavirus types reflects viral evolution. Virology (2005) 4.72
Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet (1999) 4.24
Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results. JAMA (1999) 3.37
Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst (2004) 3.20
Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. Vaccine (2006) 3.15
Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst (2003) 3.08
Are self-collected samples comparable to physician-collected cervical specimens for human papillomavirus DNA testing? A systematic review and meta-analysis. Gynecol Oncol (2007) 2.90
POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int J Cancer (2004) 2.89
Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study. BMJ (2009) 2.68
International incidence rates of invasive cervical cancer after introduction of cytological screening. Cancer Causes Control (1997) 2.52
The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period. Cancer Res (2006) 2.08
A long-term prospective study of type-specific human papillomavirus infection and risk of cervical neoplasia among 20,000 women in the Portland Kaiser Cohort Study. Cancer Epidemiol Biomarkers Prev (2011) 1.82
Risk assessment to guide the prevention of cervical cancer. Am J Obstet Gynecol (2007) 1.74
Detection of precancerous cervical lesions is differential by human papillomavirus type. Cancer Res (2009) 1.67
Cytological regression and clearance of high-risk human papillomavirus in women with an abnormal cervical smear. Lancet (2001) 1.56
The Dutch CISOE-A framework for cytology reporting increases efficacy of screening upon standardisation since 1996. J Clin Pathol (2004) 1.55
Human papillomavirus type-specific 18-month risk of high-grade cervical intraepithelial neoplasia in women with a normal or borderline/mildly dyskaryotic smear. Cancer Epidemiol Biomarkers Prev (2006) 1.47
The role of human papillomavirus testing in the management of women with low-grade abnormalities: multicentre randomised controlled trial. BJOG (2010) 1.42
Human papillomavirus testing on self-sampled cervicovaginal brushes: an effective alternative to protect nonresponders in cervical screening programs. Int J Cancer (2007) 1.37
A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: extended follow up in the ARTISTIC trial. Eur J Cancer (2011) 1.34
Long-term follow-up of cervical abnormalities among women screened by HPV testing and cytology-Results from the Hammersmith study. Int J Cancer (2008) 1.27
Risk of high-grade cervical intra-epithelial neoplasia based on cytology and high-risk HPV testing at baseline and at 6-months. Int J Cancer (2007) 1.27
HPV DNA detection and typing in cervical scrapes. Methods Mol Med (2005) 1.23
Evaluation of cervical screening strategies with adjunct high-risk human papillomavirus testing for women with borderline or mild dyskaryosis. Int J Cancer (2006) 1.20
Comparison of HPV and cytology triage algorithms for women with borderline or mild dyskaryosis in population-based cervical screening (VUSA-screen study). Int J Cancer (2010) 1.12
HPV testing as a triage for borderline or mild dyskaryosis on cervical cytology: results from the Sentinel Sites study. Br J Cancer (2011) 1.10
Cervical cancer screening in the Netherlands. Eur J Cancer (2000) 1.09
Risk of precancer and follow-up management strategies for women with human papillomavirus-negative atypical squamous cells of undetermined significance. Obstet Gynecol (2007) 1.05
Triage using HPV-testing in persistent borderline and mildly dyskaryotic smears: proposal for new guidelines. Int J Cancer (2005) 0.94
The risk of cervical cancer associated with specific types of human papillomavirus: a case-control study in a UK population. Int J Cancer (2010) 0.84
Use of high-risk human papillomavirus testing in patients with low-grade squamous intraepithelial lesions. Cancer Cytopathol (2011) 0.79
The causal relation between human papillomavirus and cervical cancer. J Clin Pathol (2002) 14.73
The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature. J Clin Oncol (2004) 2.63
Genome-wide DNA copy number alterations in head and neck squamous cell carcinomas with or without oncogene-expressing human papillomavirus. Oncogene (2006) 2.56
Endothelial cell chimerism after renal transplantation and vascular rejection. Lancet (2001) 2.35
Prevalence of papillomavirus infection in women in Ibadan, Nigeria: a population-based study. Br J Cancer (2004) 2.33
Prevalence and determinants of HPV infection among Colombian women with normal cytology. Br J Cancer (2002) 2.25
Penile cancer: epidemiology, pathogenesis and prevention. World J Urol (2008) 2.14
Risk factors for genital HPV DNA in men resemble those found in women: a study of male attendees at a Danish STD clinic. Sex Transm Infect (2002) 2.05
Increased gene copy numbers at chromosome 20q are frequent in both squamous cell carcinomas and adenocarcinomas of the cervix. J Pathol (2006) 2.02
Human papillomavirus infection in Shanxi Province, People's Republic of China: a population-based study. Br J Cancer (2006) 1.83
Cutting edge: polycomb gene expression patterns reflect distinct B cell differentiation stages in human germinal centers. J Immunol (2000) 1.83
Prevalence and determinants of human papillomavirus genital infection in men. Br J Cancer (2002) 1.83
Papillomavirus infection in rural women in southern India. Br J Cancer (2005) 1.79
Human papillomavirus detection and comorbidity: critical issues in selection of patients with oropharyngeal cancer for treatment De-escalation trials. Ann Oncol (2013) 1.77
Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. Br J Cancer (2008) 1.69
Coexpression of BMI-1 and EZH2 polycomb group genes in Reed-Sternberg cells of Hodgkin's disease. Am J Pathol (2000) 1.69
CD56+ hematological neoplasms presenting in the skin: a retrospective analysis of 23 new cases and 130 cases from the literature. Ann Oncol (2004) 1.63
Human papillomavirus infection in Shenyang City, People's Republic of China: A population-based study. Br J Cancer (2006) 1.62
Apoptosis in myocardial ischaemia and infarction. J Clin Pathol (2002) 1.59
The Dutch CISOE-A framework for cytology reporting increases efficacy of screening upon standardisation since 1996. J Clin Pathol (2004) 1.55
HPV DNA testing in population-based cervical screening (VUSA-Screen study): results and implications. Br J Cancer (2012) 1.53
C-reactive protein and complement depositions in human infarcted myocardium are more extensive in patients with reinfarction or upon treatment with reperfusion. Eur J Clin Invest (2004) 1.50
HPV infection in women with and without cervical cancer in Conakry, Guinea. Br J Cancer (2009) 1.50
Clinical validation of the cobas 4800 HPV test for cervical screening purposes. J Clin Microbiol (2011) 1.47
Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma. J Pathol (2006) 1.46
Preferential risk of HPV16 for squamous cell carcinoma and of HPV18 for adenocarcinoma of the cervix compared to women with normal cytology in The Netherlands. Br J Cancer (2006) 1.43
A CD56-negative case of blastic natural killer-cell lymphoma (agranular CD4+/CD56+ haematodermic neoplasm). Br J Dermatol (2004) 1.43
Primary screening for high risk HPV by home obtained cervicovaginal lavage is an alternative screening tool for unscreened women. J Clin Pathol (2002) 1.36
Validation of high-risk HPV tests for primary cervical screening. J Clin Virol (2009) 1.35
[Vaccines against human papillomavirus (HPV); between registration and implementation]. Ned Tijdschr Geneeskd (2008) 1.34
Prevalence and determinants of human papillomavirus infection and cervical lesions in HIV-positive women in Kenya. Br J Cancer (2012) 1.34
[Flat penile lesions in the sexual transmission of human papillomavirus]. Ned Tijdschr Geneeskd (2008) 1.32
Sequential gene promoter methylation during HPV-induced cervical carcinogenesis. Br J Cancer (2007) 1.32
A shift to a peripheral Th2-type cytokine pattern during the carcinogenesis of cervical cancer becomes manifest in CIN III lesions. J Clin Pathol (2005) 1.31
Cervical cancer screening: on the way to a shift from cytology to full molecular screening. Ann Oncol (2014) 1.30
Evaluating an educational intervention to improve the treatment of asthma in four European countries. Drug Education Project Group. Am J Respir Crit Care Med (1999) 1.28
Effects of stressful daily events on mood states: relationship to global perceived stress. J Pers Soc Psychol (1998) 1.28
Association between dense CADM1 promoter methylation and reduced protein expression in high-grade CIN and cervical SCC. J Pathol (2008) 1.28
Update on extranodal lymphomas. Conclusions of the Workshop held by the EAHP and the SH in Thessaloniki, Greece. Histopathology (2006) 1.28
Nosocomial infections in a Dutch neonatal intensive care unit: surveillance study with definitions for infection specifically adapted for neonates. J Hosp Infect (2005) 1.26
Increased Nox2 expression in human cardiomyocytes after acute myocardial infarction. J Clin Pathol (2003) 1.25
Natural T-helper immunity against human papillomavirus type 16 (HPV16) E7-derived peptide epitopes in patients with HPV16-positive cervical lesions: identification of 3 human leukocyte antigen class II-restricted epitopes. Int J Cancer (2001) 1.25
Cross-sectional comparison of an automated hybrid capture 2 assay and the consensus GP5+/6+ PCR method in a population-based cervical screening program. J Clin Microbiol (2006) 1.24
High-risk HPV type-specific clearance rates in cervical screening. Br J Cancer (2007) 1.24
Distinct BMI-1 and EZH2 expression patterns in thymocytes and mature T cells suggest a role for Polycomb genes in human T cell differentiation. J Immunol (2001) 1.20
Comparison of three different PCR methods for quantifying human papillomavirus type 16 DNA in cervical scrape specimens. J Clin Microbiol (2005) 1.20
Human papillomavirus infection in women with and without cervical cancer in Warsaw, Poland. Eur J Cancer (2008) 1.17
Age-dependent prevalence of 14 high-risk HPV types in the Netherlands: implications for prophylactic vaccination and screening. Br J Cancer (2008) 1.16
Expression of the p16(INK4a) gene product, methylation of the p16(INK4a) promoter region and expression of the polycomb-group gene BMI-1 in squamous cell lung carcinoma and premalignant endobronchial lesions. Lung Cancer (2005) 1.13
Long-term protective effect of high-risk human papillomavirus testing in population-based cervical screening. Br J Cancer (2005) 1.12
Accuracy of diagnostic imaging techniques in the diagnosis of aseptic loosening of the femoral component of a hip prosthesis: a meta-analysis. J Bone Joint Surg Br (2005) 1.10
Colonoscopy-controlled intra-individual comparisons to screen relevant neoplasia: faecal immunochemical test vs. guaiac-based faecal occult blood test. Aliment Pharmacol Ther (2009) 1.10
Human papillomavirus infection in women with and without cervical cancer in Karachi, Pakistan. Br J Cancer (2010) 1.10
HPV testing and monitoring of women after treatment of CIN 3: review of the literature and meta-analysis. Obstet Gynecol Surv (2004) 1.10